ClinicalTrials.gg

Renal Insufficiency clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,413 studies for Renal Insufficiency across more than 10 countries. 146 are recruiting or about to start. 729 of them are mainly about Renal Insufficiency (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 4 narrower conditions too, such as Renal Insufficiency, Chronic: 7,560 studies, 1,393 open.

ClinicalTrials.gov finds 7,871 studies for Renal Insufficiency. How that becomes 1,408 here

This page counts the studies the registry files under Renal Insufficiency, and those it files under no condition that list Renal Insufficiencythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 7,871Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −6,009Filed under a narrower condition, counted on its own pageRenal Insufficiency, Chronic 2,920 · Kidney Failure, Chronic 1,559 · Acute Kidney Injury 1,436 · Cardio-Renal Syndrome 48
  3. −50List Renal Insufficiency as a condition, but the registry did not file them under itMost often written as “End Stage Renal Failure on Dialysis” (22), “Renal Failure Chronic Requiring Hemodialysis” (13), and “Renal Failure Chronic Requiring Dialysis” (3). The registry filed them under other conditions only, most often Inflammation (5) and Kidney Diseases (5).
  4. −426Match it another way117 name it in the title, 6 in a keyword, and 303 by a synonym or other text the search reads.
  5. 1,386Counted here and found by its search12 of them list Renal Insufficiency in their own words; the registry filed them under no condition.
  6. +22
    Counted here, but its search does not find themThe first 20 of 22.
  7. 1,408The count on this page

Status

Completed
922
Status unknown
132
Terminated
120
Recruiting
93
Not yet recruiting
49
Withdrawn
48

Phase

Phase 1
415
Phase 2
153
Phase 3
150
Phase 4
136
Early Phase 1
8

Where

United States
553
Germany
139
France
107
Canada
79
China
61
United Kingdom
60

Who develops what

Add Renal Insufficiency to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 42 programs from 26 companies, 29 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months. Compare AstraZeneca, Eli Lilly and Merck here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
insulin degludecRecent, limited
Evidence
  • NCT05552859 · Sanofi · Phase 4 · comparator · “Insulin degludec 100 U/mL” · registered Sep 2022
Novo Nordisk A/S93% of its industry studiesUS: Novo Nordisk A/S (FDA 2015)EU: Novo Nordisk A/S (EMA 2013)11 study
TacrolimusEarlier only
Evidence
  • NCT01666951 · Veloxis Pharmaceuticals · Phase 2 · comparator · “Prograf” · registered Aug 2012
  • NCT01154387 · Tolera Therapeutics, Inc · Phase 2 · background · “Tacrolimus” · registered Jun 2010
  • NCT00817206 · Veloxis Pharmaceuticals · Phase 3 · comparator · “Prograf” · registered Dec 2008
  • NCT00765661 · Veloxis Pharmaceuticals · Phase 2 · comparator · “Prograf” · registered Oct 2008
  • NCT00369382 · Pfizer · Phase 4 · comparator · “cyclosporine or tacrolimus” · registered Aug 2006
Astellas Pharma Inc62% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 1 generic authorized00 studies
SevelamerEarlier only
Evidence
  • NCT03984760 · Panion & BF Biotech Inc. · Phase 3 · comparator · “Sevelamer Carbonate” · registered Jun 2019
  • NCT01057407 · Astellas Pharma Inc · Phase 3 · comparator · “Sevelamer hydrochloride” · registered Jan 2010
  • NCT00211939 · Nabi Biopharmaceuticals · Phase 4 · comparator · “sevelamer” · registered Sep 2005
Sanofi71% of its industry studiesEU: Sanofi (EMA 2000)00 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 42 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Renal Insufficiency studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · SGLT2 inhibitors 3 open · Alkylating agents 3 open · Diuretics 2 open · Corticosteroids 2 open

Coming up

62studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger. 8 (9%) take children under 18. 3 (3%) are for women only and 1 (1%) for men only; 15 (16%) take healthy volunteers.

Recruiting studies that take each age, of 92
AgeWomenMen
105 (5%)6 (7%)
1879 (86%)77 (84%)
3085 (92%)82 (89%)
4088 (96%)85 (92%)
5087 (95%)85 (92%)
6587 (95%)85 (92%)
7577 (84%)76 (83%)
8561 (66%)60 (65%)

Across all 1,413 studies, recruiting or not: 26% stop at 75 or younger and 9% at 65; 9% take children; 1% are for women only and 1% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Renal Insufficiency studies take

Of 231 phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 18 mo5–16 · 231 studies8 mo5–15 · 213 studies—
Phase 230 mo13–34 · 26 studies——
Phase 342 mo24–77 · 36 studies——
Phase 437 mo20–48 · 32 studies—38 mo20–67 · 29 studies
Interventional, no phase22 mo8–48 · 149 studies16 mo4–27 · 31 studies22 mo8–49 · 118 studies
Observational30 mo14–56 · 102 studies—29 mo14–58 · 87 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,413. Browse all 1,413 → or search them.